Apellis Pharmaceuticals, Inc. (APLS)
25.66
+1.10
(+4.48%)
USD |
NASDAQ |
Dec 16, 15:00
Apellis Pharmaceuticals Research and Development Expense (Annual): 327.57M for Dec. 31, 2024
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Biogen, Inc. | 1.755B |
| Amicus Therapeutics, Inc. | 109.36M |
| Fortress Biotech, Inc. | 56.88M |
| Ultragenyx Pharmaceutical, Inc. | 667.82M |
| Fulcrum Therapeutics, Inc. | 61.79M |